Studies Currently Recruiting New Patients
The Department of Dermatology is currently conducting a 18-week multicenter, placebo-controlled research study to evaluate the safety and effectiveness of a topical (applied to the scalp) investigational medication in males with male pattern hair loss.
If you are 15-49 years of age with mild or moderate male pattern hair loss in the crown area, you may be eligible to participate. All study-related office visits, tests and study medication will be provided at no charge to you. For further information contact the Dermatology Clinical Research Office at 216.445.4649.
Other Recent Studies
APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long-term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis
Protocol #: FHI 03-0-161/FG-506-06-37 IRB #:05-222.
Description: 10 year safety study to follow patients who have/had Atopic Dermatitis and applied tacrolimus (Protopic) ointment .03% or 0.1% for at least 6 weeks, continuously or intermittently. Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus exposure.
Assessment & Tracking of Long-term Alefacept Safety Study (ATLAS).
Protocol #: C-736 IRB #:8392.
Description: 5 year safety study to follow patients who have/had moderate to severe plaque psoriasis and received at least 1 (one) dose of alefacept (Amevive).
A study on Calcipotriol, a Vitamin D Analogue, as an agent to induce the differentiation of basal cell carcinoma: A Randomized Placebo-controlled Trial.
Protocol #: IRB #: 470.
Description: 8 week study to evaluate a known differentiating agent, calcipotriol, as a possible agent that might eventually help in the treatment of basal cell carcinoma. Adult subjects with diagnosed basal cell carcinoma (between 0.8 and 2.0 square centimeters) which has not been previously treated.
Upcoming Dermatology Studies
A study on Raptiva epidemiologic study of psoriasis outcomes and safety events (RESPONSE) in patients with chronic moderate to severe plaque psoriasis.
Protocol #: ACD3101g IRB #: 8464.
Description: 5 year study to evaluate long term safety of efalizumab (Raptiva) in adult subjects with moderate to severe plaque psoriasis. Subjects who are taking Raptiva and patients who are not taking Raptiva will be considered.
A Double-blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg of SC Twice Weekly in the treatment of moderate to severe Lichen Planus.
Protocol #: 20041132 IRB #: 06-036.
Description: 32 week study to assess the response of adult subjects to etanercept (Enbrel) as compared to placebo in treating the physical signs of mucosal and cutaneous lichen planus.
Observational Post-marketing Safety Surveillance Registry of Enbrel (etanercept) for the Treatment of Psoriasis.
Protocol #: 20040210 IRB #.
Description: Observational safety study to collect data on the long-term safety of Enbrel in subjects with plaque psoriasis. Subjects will be followed for 5 years. Subjects will have telephone interview every 6 months.
For More Information, please contact:
Brian Moore, MD
Research Coordinator
216.445.8454
